Allelix Biopharmaceuticals Inc. said it is filing for an initialpublic offering of shares in Canada and Europe, with shares tobe offered In the United States as a private placement.

Under Canadian regulations, no price range or share amount isannounced at filing. Burns Fry Ltd., ScotiaMcLeod Inc. andRichardson Greenshields of Canada Ltd. will underwrite theoffering.

Allelix of Mississauga, Ontario, is developingbiopharmaceuticals for tissue repair and inflammation.

Before the offering, Allpharmix Inc. holds 34.9 percent ofAllelix shares. Other major shareholders include FederalBusiness Development Bank and Glaxo Canada Inc., with 10.5percent each; MDS Health Ventures Inc. with 9.7 percent; TheGreat West Life Assurance Co. with 9.6 percent; OntarioDevelopment Corp. with 8 percent; and Eli Lilly Canada Inc.with 6.4 percent.

(c) 1997 American Health Consultants. All rights reserved.